News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
409,877 Results
Type
Article (33491)
Company Profile (67)
Press Release (376310)
Multimedia
Podcasts (63)
Webinars (6)
Section
Business (115149)
Career Advice (1379)
Deals (24280)
Drug Delivery (100)
Drug Development (60308)
Employer Resources (110)
FDA (10184)
Job Trends (9252)
News (214830)
Policy (25785)
Tag
Academia (1864)
Accelerated approval (14)
Adcomms (24)
Allergies (85)
Alliances (42531)
ALS (86)
Alzheimer's disease (1224)
Antibody-drug conjugate (ADC) (138)
Approvals (10184)
Artificial intelligence (233)
Autoimmune disease (26)
Automation (12)
Bankruptcy (239)
Best Places to Work (7763)
BIOSECURE Act (16)
Biosimilars (105)
Biotechnology (45)
Bladder cancer (77)
Brain cancer (40)
Breast cancer (288)
Cancer (2458)
Cardiovascular disease (210)
Career advice (1159)
Career pathing (22)
CAR-T (150)
CDC (42)
Cell therapy (392)
Cervical cancer (20)
Clinical research (49644)
Collaboration (967)
Company closure (3)
Compensation (703)
Complete response letters (35)
COVID-19 (2562)
CRISPR (52)
C-suite (244)
Cystic fibrosis (70)
Data (2599)
Decentralized trials (1)
Denatured (9)
Depression (64)
Diabetes (307)
Diagnostics (3648)
Digital health (16)
Diversity (5)
Diversity, equity & inclusion (35)
Drug discovery (123)
Drug pricing (136)
Drug shortages (31)
Duchenne muscular dystrophy (146)
Earnings (42085)
Editorial (46)
Employer branding (18)
Employer resources (100)
Events (47540)
Executive appointments (431)
FDA (11709)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (7)
Funding (671)
Gene editing (105)
Generative AI (19)
Gene therapy (333)
GLP-1 (815)
Government (4301)
Grass and pollen (5)
Guidances (259)
Healthcare (11530)
HIV (40)
Huntington's disease (25)
IgA nephropathy (45)
Immunology and inflammation (131)
Immuno-oncology (14)
Indications (38)
Infectious disease (2753)
Inflammatory bowel disease (94)
Inflation Reduction Act (9)
Influenza (77)
Intellectual property (102)
Interviews (243)
IPO (10570)
IRA (46)
Job creations (1826)
Job search strategy (992)
Kidney cancer (8)
Labor market (37)
Layoffs (348)
Leadership (13)
Legal (7113)
Liver cancer (60)
Longevity (11)
Lung cancer (359)
Lymphoma (186)
Machine learning (19)
Management (32)
Manufacturing (372)
MASH (88)
Medical device (6016)
Medtech (6024)
Mergers & acquisitions (14340)
Metabolic disorders (816)
Multiple sclerosis (76)
NASH (20)
Neurodegenerative disease (117)
Neuropsychiatric disorders (35)
Neuroscience (1819)
NextGen: Class of 2025 (3743)
Non-profit (2801)
Now hiring (10)
Obesity (435)
Opinion (226)
Ovarian cancer (74)
Pain (80)
Pancreatic cancer (115)
Parkinson's disease (151)
Partnered (15)
Patents (238)
Patient recruitment (148)
Peanut (41)
People (26781)
Pharmaceutical (19)
Pharmacy benefit managers (14)
Phase I (15000)
Phase II (21575)
Phase III (17494)
Pipeline (1854)
Policy (226)
Postmarket research (1863)
Preclinical (6250)
Press Release (28)
Prostate cancer (132)
Psychedelics (36)
Radiopharmaceuticals (223)
Rare diseases (384)
Real estate (2641)
Recruiting (46)
Regulatory (16926)
Reports (24)
Research institute (1617)
Resumes & cover letters (210)
Rett syndrome (10)
RNA editing (7)
RSV (60)
Schizophrenia (92)
Series A (98)
Series B (74)
Service/supplier (4)
Sickle cell disease (43)
Special edition (10)
Spinal muscular atrophy (143)
Sponsored (22)
Startups (2009)
State (1)
Stomach cancer (12)
Supply chain (68)
Tariffs (69)
The Weekly (53)
Vaccines (895)
Venture capital (47)
Weight loss (300)
Women's health (24)
Worklife (10)
Date
Last 7 days (305)
Last 30 days (1332)
Last 365 days (20260)
2025 (14100)
2024 (22587)
2023 (25478)
2022 (33712)
2021 (36283)
2020 (34396)
2019 (28268)
2018 (21535)
2017 (20523)
2016 (18928)
2015 (21726)
2014 (16137)
2013 (12995)
2012 (13786)
2011 (14549)
2010 (13211)
Location
Africa (591)
Alabama (40)
Alaska (3)
Arizona (102)
Arkansas (5)
Asia (26701)
Australia (4775)
California (5205)
Canada (1637)
China (557)
Colorado (211)
Connecticut (234)
Delaware (163)
Europe (64267)
Florida (794)
Georgia (173)
Hawaii (3)
Idaho (30)
Illinois (390)
India (31)
Indiana (259)
Iowa (14)
Japan (197)
Kansas (70)
Kentucky (19)
Louisiana (12)
Maine (30)
Maryland (807)
Massachusetts (3722)
Michigan (133)
Minnesota (192)
Mississippi (1)
Missouri (61)
Montana (20)
Nebraska (10)
Nevada (60)
New Hampshire (26)
New Jersey (1589)
New Mexico (16)
New York (1514)
North Carolina (661)
North Dakota (5)
Northern California (2436)
Ohio (153)
Oklahoma (7)
Oregon (10)
Pennsylvania (1091)
Puerto Rico (8)
Rhode Island (16)
South America (815)
South Carolina (20)
South Dakota (1)
Southern California (1974)
Tennessee (66)
Texas (658)
United States (18717)
Utah (118)
Virginia (143)
Washington D.C. (43)
Washington State (397)
West Virginia (2)
Wisconsin (41)
409,877 Results for "novartis ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
September 9, 2025
·
10 min read
Mergers & acquisitions
Novartis Deals in Cardio Again, Dropping $1.4B To Acquire Tourmaline
Novartis has been investing heavily in its cardiovascular pipeline this year, forging partnerships with Flagship startup ProFound Therapeutics and China’s Argo Biopharmaceutical, among others.
September 9, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment
Novartis and Argo Biopharma go back to January 2024, when the pharma first bet up to $4.165 billion across two RNAi agreements targeting cardiovascular diseases.
September 3, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
Novartis, BioArctic Partner To Penetrate the Blood-Brain Barrier
Novartis has bet up to $772 million to gain access to BioArctic’s BrainTransporter platform, which was leveraged in a partnership with Eisai to produce Leqembi.
August 27, 2025
·
1 min read
·
Tristan Manalac
Mergers & Acquisitions
Novartis’ Busy BD Team Keeps 2025 Bolt-On Deal Promises
Executives at Novartis have not been shy about a desire to buy more companies, with cardiovascular a big focus. In total, the Swiss pharma has put $17.23 billion on the line in M&A and licensing deals this year.
September 9, 2025
·
2 min read
·
Annalee Armstrong
Deals
Arrowhead Nabs up to $2B Novartis Commitment for siRNA Parkinson’s Program
Novartis is licensing ARO-SNCA, a preclinical siRNA therapy for synucleinopathies, a group of neurodegenerative disorders including Parkinson’s disease.
September 2, 2025
·
1 min read
·
Annalee Armstrong
Startups
Six Startups Changing The Way We Age
Armed with the latest biological knowledge and cutting-edge computational techniques—and, of course, investor dollars—these six biotechs are playing in the largely underappreciated longevity space, developing therapies that may improve the quality of aging.
July 9, 2025
·
11 min read
·
Tristan Manalac
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
I&I
Novartis Drops up to $1B+ for Drug Discovery Deal With Matchpoint
The partnership with Matchpoint Therapeutics gets Novartis global rights on all molecules for several unannounced inflammatory diseases identified through the biotech’s discovery platform.
July 24, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
September 2, 2025
·
6 min read
1 of 40,988
Next
